First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Peters, Solange; Scherpereel, Arnaud; Cornelissen, Robin; Oulkhouir, Youssef; Greillier, Laurent; Ma, Kaplan; Talbot, Thomas; Monnet, I.; Hiret, Sandrine; Baas, P.; K. Nowak, Anna; Fujimoto, Nobukazu; S. Tsao, Anne; S. Mansfield, Aaron; Popat, Sanjay; Zhang, X.; Hu, Nan; Balli, David; Spires, Thomas; Zalcman, Gérard

doi:10.1016/j.annonc.2022.01.074

Public

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Published in Annals of Oncology • Feb 3, 2022

Authors:

Solange Peters

Arnaud Scherpereel

Robin Cornelissen

Abstract

BACKGROUND: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. PATIENTS AND...

Subject

Medicine

Nivolumab

Ipilimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!